TNSN97042A1 - Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant. - Google Patents

Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant.

Info

Publication number
TNSN97042A1
TNSN97042A1 TNTNSN97042A TNSN97042A TNSN97042A1 TN SN97042 A1 TNSN97042 A1 TN SN97042A1 TN TNSN97042 A TNTNSN97042 A TN TNSN97042A TN SN97042 A TNSN97042 A TN SN97042A TN SN97042 A1 TNSN97042 A1 TN SN97042A1
Authority
TN
Tunisia
Prior art keywords
preparation
formulations containing
pharmaceutical formulations
therapeutics
derivatives useful
Prior art date
Application number
TNTNSN97042A
Other languages
English (en)
Inventor
Eric Mowbray Charles
Stobie Alan
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of TNSN97042A1 publication Critical patent/TNSN97042A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION PROPOSE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1 ET R2 REPRESENTENT C1 OU DES RADICAUX ORGANIQUES, ET R3 REPRESENTE DES RADICAUX ORGANIQUES, AINSI QUE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES FORMULATIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DES COMPOSES ET FORMULATIONS PHARMACEUTIQUES COMME ANXIOLYTIQUES, ANTICONVULSIVANTS, ANALGESIQUES ET NEUROPROTECTEURS.
TNTNSN97042A 1996-03-01 1997-02-28 Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant. TNSN97042A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9604400.3A GB9604400D0 (en) 1996-03-01 1996-03-01 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
TNSN97042A1 true TNSN97042A1 (fr) 2005-03-15

Family

ID=10789694

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97042A TNSN97042A1 (fr) 1996-03-01 1997-02-28 Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant.

Country Status (13)

Country Link
US (1) US5863917A (fr)
EP (1) EP0792874A1 (fr)
JP (1) JPH101474A (fr)
AP (1) AP9700933A0 (fr)
AR (1) AR006754A1 (fr)
AU (1) AU1877497A (fr)
CA (1) CA2198687A1 (fr)
GB (1) GB9604400D0 (fr)
ID (1) ID19871A (fr)
MA (1) MA26421A1 (fr)
MX (1) MXPA97001590A (fr)
TN (1) TNSN97042A1 (fr)
WO (1) WO1997031902A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
AU6870600A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
JP5351930B2 (ja) * 2004-02-04 2013-11-27 株式会社ファンケル 抗不安剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220124A (ja) 1990-01-24 1991-09-27 Sumitomo Pharmaceut Co Ltd グルタミン酸拮抗剤
DK69790D0 (da) 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse
DE69113115T2 (de) 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
EP0647137B1 (fr) 1992-06-22 2008-08-13 The Regents Of The University Of California Antagonistes des recepteurs de glycine et leur utilisation
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
US5863917A (en) 1999-01-26
MA26421A1 (fr) 2004-12-20
AU1877497A (en) 1997-09-16
CA2198687A1 (fr) 1997-09-01
WO1997031902A1 (fr) 1997-09-04
JPH101474A (ja) 1998-01-06
GB9604400D0 (en) 1996-05-01
AR006754A1 (es) 1999-09-29
MXPA97001590A (es) 2004-09-13
ID19871A (id) 1998-08-13
AP9700933A0 (en) 1997-04-30
EP0792874A1 (fr) 1997-09-03

Similar Documents

Publication Publication Date Title
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN97023A1 (fr) Derives de triazole utiles en therapeutique, procedes pour leur preparation et compositions les contenant.
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98238A1 (fr) Macrolides nouveaux
MY130668A (en) Isothiazole derivatives useful as anticancer agents
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN05165A1 (fr) Derives de pyrrolopyrimidine
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant